REG - LungLife AI, INC - LungLB® publication in peer-reviewed journal

LungLife AIAnnouncement

02/10/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241002:nRSB4811Ga&default-theme=true

RNS Number : 4811G  LungLife AI, INC  02 October 2024

LungLife AI, Inc.

(the "Company" or "LungLife")

 

LungLB® analytical validation accepted for publication in peer-reviewed
journal

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces the acceptance for publication of data confirming analytical
performance of the Company's blood-based LungLB® test in the journal BMC
Pulmonary Medicine.

 

Springer Nature's BMC Pulmonary Medicine is a globally recognised
peer-reviewed medical journal with articles covering all aspects of the
prevention, diagnosis and management of pulmonary and associated disorders.
The full publication, entitled "Analytical Validation of the LungLB® test: a
4-color fluorescence in-situ hybridization assay for the evaluation of
indeterminate pulmonary nodules" can be accessed here
https://doi.org/10.1186/s12890-024-03280-7
(https://urldefense.com/v3/__https:/doi.org/10.1186/s12890-024-03280-7__;!!NLFGqXoFfo8MMQ!uQWPbmMCpP6Q6BkdNgQl9MfymHptXLxrLbftnhNsEGlKUTCfVOnMNJgOuyCeYLagURA7wiA7j6Vk30Zgzb-aGH5ncj_zp8l1$)
.

 

Publication in scientific journals is a crucial step in the commercialisation
of LungLB® as the peer-review process supports the verification of the
reliability and credibility of the research, building trust and confidence
within the scientific and medical communities.

 

This publication adds to the growing body of evidence supporting LungLB®,
including clinical validity and health economics data published in 2023, and
is a key element in obtaining coverage for Medicare reimbursement, opening the
test up for Medicare patients and increasing the likelihood of the test being
adopted by centres.

 

As a reminder, the analytic validation experiments were done in accordance
with the globally recognised Clinical and Laboratory Standards Institute
(CLSI) guidelines, of which the US FDA recognises over 100 CLSI consensus
standards, to evaluate sample stability and assay reproducibility under a
variety of clinical and laboratory conditions. Collectively, the results
demonstrate the LungLB® test worked consistently well, no matter which lab
technician was running it, when it was done, or which batch of materials was
used. This is important as it shows that the test is reliable and
well-designed.

 

Eric Vail MD, Director of Molecular Pathology at Cedars Sinai Medical Center,
Laboratory Director of LungLife AI, and co-author on the study commented:

"I am delighted that the analytic validation has been published in a highly
regarded journal. Novel diagnostic tests must undergo rigorous analytical
testing prior to clinical use to demonstrate accuracy and reliability in
routine laboratory settings. The data show to the scientific and medical
community that the LungLB® test is robust and suitable to everyday clinical
use."

 

Paul Pagano, Chief Executive Officer of LungLife, added:

 

"Having the results of our study peer-reviewed and published is a significant
milestone, validating the scientific rigour of our research. This achievement
is a key part of our commercialisation strategy to build a bank of evidence of
the efficacy and utility of our testing. It underscores both the credibility
of our LungLB® test and provides greater confidence in its use, and
importantly, by raising awareness about the test it supports our commitment to
expanding access for those who need it most."

 

 

For further information please contact:

 

 LungLife AI, Inc.                                   www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                    via investors@lunglifeai.com
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Lydia Zychowska / Sara Wallace

 Goodbody (Joint Broker)                             Tel: +44 (0) 20 3841 6202
 Tom Nicholson / Cameron Duncan

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

Our Purpose is to be a driving force in the early detection to lung cancer.
And our Vision is to invert the 20:80 ratio such that in years to come at
least 80% of lung cancer is detected early.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMBBMTMTIMBBI